Verastem, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.verastem.com

Market Cap $438.69M
Debt $72.22M
Cash $117.81M
EV $393.10M
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$148.88M
EBIT	-$131.07M
ROA	-100%
Equity	-$32.43M
Growth Stability	1
PE	-2.95
PB	-13.53
Price/Cash	0.27
Debt/Equity	-2.23
Sales CAGR	-2%
Equity CAGR	-7%
Earnings Growth YoY	54%
Earnings Growth QoQ	-19%
Sales CAGR 5Y	-9%

Equity CAGR 5Y	-22%
Equity CAGR 3Y	-23%
Market Cap	$438.69M
Assets	$131.70M
Total Debt	$72.22M
Cash	$117.81M
Shares Outstanding	51.49M
EV	393.1M
Working Capital	89.08M
Current Ratio	3.5
Shares Growth 3y	49%
Equity Growth QoQ	12%
Equity Growth YoY	-229%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.

SEC Filings

Direct access to Verastem, Inc. (VSTM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Verastem, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Verastem, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Verastem, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Verastem, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-271%	-855%	-77%	-3K%	-3K%	-	-1K%	-
ROA	-	-44%	-76%	-26%	-91%	-32%	-57%	-77%	-58%	-113%	-100%
ROE	-	-50%	-118%	-58%	-2K%	-59%	-81%	-156%	-152%	452%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-0.49	-0.57	-0	-	-	-	-
Debt over Equity	-	-	260.04	0.77	9.56	0.17	0	0.53	0.7	-1.41	-2.23
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-2.23)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-35%	407%	-98%	26%	-	-	-9%
Earnings YoY growth	-	-37%	86%	7%	106%	-55%	5%	4%	18%	50%	-
Equity YoY growth	-	-29%	-20%	115%	-94%	2K%	-24%	-46%	21%	-150%	-22%
FCF YoY growth	-	-35%	-	-	82%	-76%	60%	-	-	-	-